From Policy to Practice: How Reimbursement is Shaping RDN Adoption

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Boston Scientific Corporation; Shockwave Medical</li><li>Advisory Board - Recor Medical; Procyrion; Medtronic</li><li>Equity/Stock(s)/Options - Vantis</li></ul>